

*Contains Nonbinding Recommendations*  
**Draft Guidance on Alendronate Sodium**

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

**Active Ingredient:** Alendronate Sodium

**Form/Route:** Tablet/Oral

**Recommended Studies:** 1 study

Type of study: Fasting

Design: Single-dose, two-way crossover *in-vivo*

Strength: 70 mg

Subjects: Healthy males and nonpregnant females, general population

Additional Comments: (1) A highly selective assay for alendronate capable of at least low ng/mL lower limit of quantitation should be utilized. (2) Applicants may consider using a reference-scaled average bioequivalence approach for alendronate. If using this approach, please provide evidence of high variability in the bioequivalence parameters of AUC and/or C<sub>max</sub> (i.e., within-subject variability  $\geq 30\%$ ). For details on the method for statistical analysis using the reference-scaled average bioequivalence approach, please refer to the Draft Guidance on Progesterone Oral Capsules at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM209294.pdf>.

---

**Analytes to measure (in appropriate biological fluid):** Alendronate in plasma

**Bioequivalence based on (90% CI):** Alendronate

**Waiver request of in-vivo testing:** 5 mg, 10 mg, 35 mg, and 40 mg based on (i) an acceptable bioequivalence study on the 70 mg strength, (ii) proportional similarity of the formulations across all strengths, and (iii) acceptable in vitro dissolution testing of all strengths.

**Dissolution test method and sampling times:**

Please note that a Dissolution Methods Database is available to the public at the OGD website at <http://www.accessdata.fda.gov/scripts/cder/dissolution/index.cfm>. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.